DXM + Fluoxetine, paroxetine

Group assessment

This PHI covers the named group; its members do not have separate PHI ratings.

PHI 7 to 8

https://dxm-atlas.org/en/interactions/fluoxetine-paroxetine/

Compare

Key points for this combination

Serotonergic effects plus strong CYP2D6 inhibition. Increased DXM exposure [2, 4]

General concepts in this text

CYP2D6

One of the CYP enzymes involved in processing drugs.

Inhibition means reducing enzyme activity; it can change the processing of drugs.

Sources: CYP2D6

Serotonin

A neurotransmitter: a substance that carries a chemical signal from a nerve cell.

There are different serotonin receptors in the brain and other parts of the body. The response to the signal depends on the receptor and its location.

Sources: Serotonin

Drug exposure

Description of how much of a medicine is present in the body, using its concentrations.

Cmax describes the concentration peak; AUC combines concentrations over time.

Sources: Drug exposure

How well is this understood?

Mechanism confidence: high

Confidence in the mechanism: high

M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.

Method
Confidence in human DXM data: medium

Confidence in direct human evidence involving DXM: medium

M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.

Method

How to read ratings and study limits

How do the substances interact?

Can the amount reaching the body change?

Mechanism: 2D6 — CYP2D6 metabolism
ⓘ

CYP2D6

One of the CYP enzymes involved in processing drugs.

Inhibition means reducing enzyme activity; it can change the processing of drugs.

Sources: CYP2D6
  1. CYP2D6 inhibition persistence after discontinuation → In a fluoxetine study using DXM as a probe, CYP2D6 inhibition persisted for two weeks after fluoxetine was discontinued [50]. Finding below: Finding [50]

How can the effects add up?

Mechanism: SERT — Serotonin reuptake
ⓘ

SERT

A transporter protein involved in serotonin reuptake.

Inhibiting transport differs from acting on receptors.

Sources: SERT

What remains unknown?

Study times describe the endpoint studied; label intervals are tied to the product and direction of prescribing.

Sources

Check the review’s wording

Serotonergic effects plus strong CYP2D6 inhibition; increased DXM exposure [2, 4]

Combination row in the review: 2D6 — CYP2D6 metabolism; SERT — Serotonin reuptake

Evidence and sources

Research publication

[50] · Effect of venlafaxine versus fluoxetine on metabolism of dextromethorphan, a CYP2D6 probe · 2001

Finding [50]

What was found?

In a fluoxetine study using DXM as a probe, CYP2D6 inhibition persisted for two weeks after fluoxetine was discontinued [50].

CYP2D6 inhibition persistence after discontinuation

2 weeks

What limits this finding?

Study times describe the endpoint studied; label intervals are tied to the product and direction of prescribing.

Scientific review: Persistent interactions after subjective effects have ended

Related entries

Reference

Open the source and related combinations →